Cargando…

Novel Approaches to Target Mutant FLT3 Leukaemia

SIMPLE SUMMARY: Acute myeloid leukemia (AML) is a haematologic disease in which oncogenic mutations in the receptor tyrosine kinase FLT3 frequently lead to leukaemic development. Potent treatment of AML patients is still hampered by inefficient targeting of leukemic stem cells expressing constitutiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Müller, Jörg P., Schmidt-Arras, Dirk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7600363/ https://www.ncbi.nlm.nih.gov/pubmed/33003568 http://dx.doi.org/10.3390/cancers12102806

Ejemplares similares

Synergistic killing of FLT3ITD-positive AML cells by combined inhibition of tyrosine-kinase activity and N-glycosylation
por: Tsitsipatis, Dimitrios, et al.
Publicado: (2017)

Further Activation of FLT3 Mutants by FLT3 Ligand
por: Zheng, Rui, et al.
Publicado: (2011)

Selectively targeting FLT3-ITD mutants over FLT3- wt by a novel inhibitor for acute myeloid leukemia
por: Wang, Aoli, et al.
Publicado: (2020)

FLT3‐targeted therapy restores GATA1 pathway function in NPM1/FLT3‐ITD mutated acute myeloid leukaemia
por: Sorcini, D, et al.
Publicado: (2023)

Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel Approaches
por: Tecik, Melisa, et al.
Publicado: (2022)

Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance
por: Staudt, Dilana, et al.
Publicado: (2018)

Reversible Resistance Induced by FLT3 Inhibition: A Novel Resistance Mechanism in Mutant FLT3-Expressing Cells
por: Weisberg, Ellen, et al.
Publicado: (2011)

OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia
por: Eisfelder, Bartholomew J., et al.
Publicado: (2021)

A novel approach for relapsed/refractory FLT3(mut+) acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib
por: Li, Ke-xin, et al.
Publicado: (2022)

Identification of FLT3 and NPM1 Mutations in Patients with Acute Myeloid Leukaemia
por: Yusoff, Yuslina Mat, et al.
Publicado: (2019)

Oncogenic roles of PRL-3 in FLT3-ITD induced acute myeloid leukaemia
por: Park, Jung Eun, et al.
Publicado: (2013)

S124: PHOSPHOPROTEOMICS ACCURATELY PREDICTS RESPONSES TO MIDOSTAURIN PLUS CHEMOTHERAPY IN TWO INDEPENDENT COHORTS OF FLT3 MUTANT-POSITIVE ACUTE MYELOID LEUKAEMIA
por: Dokal, Arran, et al.
Publicado: (2023)

Correction: A novel approach for relapsed/refractory FLT3(mut+)acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib
por: Li, Ke-xin, et al.
Publicado: (2022)

Computer simulations of the signalling network in FLT3 (+)-acute myeloid leukaemia – indications for an optimal dosage of inhibitors against FLT3 and CDK6
por: Buetti-Dinh, Antoine, et al.
Publicado: (2018)

The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations
por: Weisberg, Ellen, et al.
Publicado: (2020)

Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3
por: Wachholz, Vanessa, et al.
Publicado: (2021)

Targeting C/EBPα overcomes primary resistance and improves the efficacy of FLT3 inhibitors in acute myeloid leukaemia
por: Wang, Hanlin, et al.
Publicado: (2023)

Combination strategies to overcome drug resistance in FLT(+) acute myeloid leukaemia
por: Yang, Jingmei, et al.
Publicado: (2023)

LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia
por: Yu, Zhou, et al.
Publicado: (2021)

Wild‐type FLT3 and FLT3 ITD exhibit similar ligand‐induced internalization characteristics
por: Kellner, Fabienne, et al.
Publicado: (2020)

Therapeutic Vulnerabilities in FLT3-Mutant AML Unmasked by Palbociclib
por: Uras, Iris Z., et al.
Publicado: (2018)

Disrupting autophagy in FLT3-mutant acute myeloid leukemia
por: Grant, Steven
Publicado: (2022)

Targeting FLT3 Mutations in Acute Myeloid Leukemia
por: El Fakih, Riad, et al.
Publicado: (2018)

The curious case of IDH mutant acute myeloid leukaemia: biochemistry and therapeutic approaches
por: Gruber, Emily, et al.
Publicado: (2023)

Flt3-ITD mutations in a mouse model of radiation-induced acute myeloid leukaemia
por: Finnon, R, et al.
Publicado: (2012)

FLT3‐ITD mutations in acute myeloid leukaemia – molecular characteristics, distribution and numerical variation
por: Engen, Caroline, et al.
Publicado: (2021)

Clinical and molecular features of FLT3 juxtamembrane domain missense mutations in acute myeloid leukaemia
por: Jensen, Christopher E., et al.
Publicado: (2022)

The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors
por: Lim, Sung Hee, et al.
Publicado: (2016)

Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML
por: Lam, Stephen S.Y., et al.
Publicado: (2020)

Potential targeting of FLT3 acute myeloid leukemia
por: Ambinder, Alexander J., et al.
Publicado: (2020)

Resistance to targeted therapies: delving into FLT3 and IDH
por: Desikan, Sai Prasad, et al.
Publicado: (2022)

Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia
por: Murray, Heather C., et al.
Publicado: (2020)

Momelotinib is a highly potent inhibitor of FLT3-mutant AML
por: Azhar, Mohammad, et al.
Publicado: (2022)

Sex disparity in acute myeloid leukaemia with FLT3 internal tandem duplication mutations: implications for prognosis
por: Hellesøy, Monica, et al.
Publicado: (2021)

The Flt3L/Flt3 Axis in Dendritic Cell Biology and Cancer Immunotherapy
por: Cueto, Francisco J., et al.
Publicado: (2021)

81030 Utilizing a synergistic drug combination to target relapsed/refractory FLT3 mutant AML
por: Jones, LaQuita, et al.
Publicado: (2021)

Novel AXL-targeted agents overcome FLT3 inhibitor resistance in FLT3-ITD(+) acute myeloid leukemia cells
por: Liu, Yi, et al.
Publicado: (2021)

Selective FLT3 inhibition of FLT3-ITD(+) acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns
por: Moore, Andrew S., et al.
Publicado: (2012)

Clinico-Haematologic association and prognostic relevance of NPM1 and FLT3-ITD mutations in acute Myeloid Leukaemia
por: Mahmood, Rafia, et al.
Publicado: (2019)

BETing on rational combination therapy in mutant FLT3 acute myeloid leukemia
por: Stone, Richard M.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0jg24516r9e7mmv2akjjj31lfj